Monolith Management Ltd Invests $4.63 Million in Hims & Hers Health, Inc. (NYSE:HIMS)

Monolith Management Ltd purchased a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 191,500 shares of the company's stock, valued at approximately $4,630,000. Hims & Hers Health accounts for 2.4% of Monolith Management Ltd's holdings, making the stock its 15th biggest position. Monolith Management Ltd owned approximately 0.09% of Hims & Hers Health as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in HIMS. HighTower Advisors LLC bought a new position in Hims & Hers Health during the third quarter worth about $207,000. MML Investors Services LLC bought a new position in Hims & Hers Health during the third quarter worth about $197,000. Barclays PLC boosted its position in shares of Hims & Hers Health by 9.7% in the third quarter. Barclays PLC now owns 308,363 shares of the company's stock valued at $5,680,000 after acquiring an additional 27,231 shares during the period. Sanctuary Advisors LLC boosted its position in shares of Hims & Hers Health by 26.8% in the third quarter. Sanctuary Advisors LLC now owns 26,057 shares of the company's stock valued at $480,000 after acquiring an additional 5,505 shares during the period. Finally, Principal Financial Group Inc. grew its stake in Hims & Hers Health by 102.0% during the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company's stock valued at $5,349,000 after acquiring an additional 146,621 shares in the last quarter. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health Stock Up 1.5 %

Shares of Hims & Hers Health stock traded up $0.42 during trading on Monday, reaching $28.51. 32,720,529 shares of the stock were exchanged, compared to its average volume of 15,718,007. The stock's fifty day moving average is $34.24 and its 200 day moving average is $31.08. The firm has a market cap of $6.33 billion, a price-to-earnings ratio of 64.80 and a beta of 1.65. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In related news, COO Melissa Baird sold 33,333 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $25.78, for a total transaction of $859,324.74. Following the completion of the sale, the chief operating officer now owns 805,083 shares of the company's stock, valued at $20,755,039.74. This trade represents a 3.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the completion of the sale, the chief executive officer now directly owns 97,687 shares of the company's stock, valued at approximately $5,692,221.49. This trade represents a 56.74 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 712,998 shares of company stock valued at $27,992,450. Corporate insiders own 17.71% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on HIMS shares. Bank of America raised their price target on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an "underperform" rating in a report on Tuesday, March 18th. Morgan Stanley cut Hims & Hers Health from an "overweight" rating to an "equal weight" rating and boosted their target price for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Leerink Partners boosted their target price on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research report on Tuesday, February 25th. Citigroup reduced their target price on Hims & Hers Health from $27.00 to $25.00 and set a "sell" rating for the company in a research report on Friday. Finally, BTIG Research started coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a "buy" rating and a $35.00 target price for the company. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $38.08.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.